Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.

摘要: Abstract We performed a retrospective study comparing treatment patterns and overall survival (OS) in chronic lymphocytic leukemia (CLL) patients with the advent of ibrutinib to provide current real-world data. Methods Using provincial population-based database, we analyzed CLL who received upfront British Columbia before availability (1984–2014), during access for: relapse only (2014–2015) for (with 17p deletion or unfit chemotherapy) (2015–2016). Analysis included up third-line treatment. Results Of 1729 meeting inclusion criteria (median age, 66 years; 1466, period 1; 140, 2; 123, 3), FR was most common first-line therapy (35.8 %, 54.3 % 40.7 periods 1–3, respectively) 18.7 3. The therapies were chemoimmunotherapy (36.1 55.6 1 2, second-line; 29.2 1, third-line) (69.8 3, 46.4 70.3 2 third-line). OS improved treated 2–3 over not reached vs. 11.9 years, p  Conclusion Ibrutinib has replaced as preferred relapse. Overall time ibrutinib.